- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04539392
Bedömning av det infertila parets sexualitet (INFEXO)
Bedömning av det infertila parets sexualitet: Prospektiv kohortstudie
The study hypothesis is that infertile couples experience an impact of their sexuality impacted during the diagnostic process carried out as part of the medically assisted procreation assessment, and also by the announcement of the possible cause of the couple's infertility. It is also conceivable that a disorder of the couple's sexuality forms the origin of, or is a contributor to, infertility.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studieorter
-
-
-
Nîmes, Frankrike
- CHU de Nimes
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
80 heterosexual infertile couples (according to the WHO definition) followed at the Nîmes University Hospital in the Urology / Gynecology departments.
Beskrivning
Inclusion Criteria:
- Couple in which each of the two partners has signed the consent form which is presented separately and independently of their partner.
- The patient must be a member or beneficiary of a health insurance plan
- Heterosexual infertile couple (according to the WHO definition) monitored at the Nîmes University Hospital in the urology / gynecology departments.
Adult patient (≥18 years old) and under 43 years old for women, 60 years old for men
Exclusion Criteria:
- The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study
- One member of the couple refuses to sign the consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Patient without good level of written and spoken French
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Infertilt par
|
Panel of questionnaires assessing sexuality, relationship satisfaction, and body image |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Sexuality of the female of the couple
Tidsram: 2 weeks after inclusion (start of MAP)
|
Female sexual function index: The total score is between 2 and 36 with sexual dysfunction indicated for scores below 26.55 |
2 weeks after inclusion (start of MAP)
|
|
Sexuality of the female of the couple
Tidsram: 1 month after ovarian ponction (end of MAP)
|
Female sexual function index: The total score is between 2 and 36 with sexual dysfunction indicated for scores below 26.55 |
1 month after ovarian ponction (end of MAP)
|
|
Sexuality of the male of the couple
Tidsram: 2 weeks after inclusion (start of MAP)
|
Male Sexual Health Questionnaire |
2 weeks after inclusion (start of MAP)
|
|
Sexuality of the male of the couple
Tidsram: 1 month after ovarian ponction (end of MAP)
|
Male Sexual Health Questionnaire |
1 month after ovarian ponction (end of MAP)
|
|
Ejactulation of the male of the couple
Tidsram: 2 weeks after inclusion (start of MAP)
|
Premature Ejaculation Profile |
2 weeks after inclusion (start of MAP)
|
|
Ejactulation of the male of the couple
Tidsram: 1 month after ovarian ponction (end of MAP)
|
Premature Ejaculation Profile |
1 month after ovarian ponction (end of MAP)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Sexuality of the female of the couple
Tidsram: 1 month after ovarian ponction (end of MAP)
|
Female sexual function index: The total score is between 2 and 36 with sexual dysfunction indicated for scores below 26.55 |
1 month after ovarian ponction (end of MAP)
|
|
Sexuality of the male of the couple
Tidsram: 1 month after ovarian ponction (end of MAP)
|
Male Sexual Health Questionnaire |
1 month after ovarian ponction (end of MAP)
|
|
Body satisfaction and global self-perception of both members of the couple
Tidsram: 2 weeks after inclusion (start of MAP)
|
Questionnaire de satisfaction corporelle et de perception globale de soi (QSCPGS): total score ranges from -100 to +100. |
2 weeks after inclusion (start of MAP)
|
|
Body satisfaction and global self-perception of both members of the couple
Tidsram: 1 month after ovarian ponction (end of MAP)
|
Questionnaire de satisfaction corporelle et de perception globale de soi (QSCPGS): total score ranges from -100 to +100. |
1 month after ovarian ponction (end of MAP)
|
|
Relationship satisfaction of both members of the couple
Tidsram: 2 weeks after inclusion (start of MAP)
|
Dyadic Adjustment Scale-16 Distress if score less than 92 and without distress if the score is higher than 107 |
2 weeks after inclusion (start of MAP)
|
|
Relationship satisfaction of both members of the couple
Tidsram: 1 month after ovarian ponction (end of MAP)
|
Dyadic Adjustment Scale-16 Distress if score less than 92 and without distress if the score is higher than 107 |
1 month after ovarian ponction (end of MAP)
|
|
Self-esteem of both members of the couple
Tidsram: 2 weeks after inclusion (start of MAP)
|
Rosenberg self-esteem scale: The score is between 10 and 40. A score below 25 indicates very low self-esteem. A score between 25 and 31 indicates low self-esteem. A score between 31 and 34 indicates average self-esteem. A score between 34 and 39 indicates strong self-esteem. A score above 39 indicates very high self-esteem. |
2 weeks after inclusion (start of MAP)
|
|
Self-esteem of both members of the couple
Tidsram: 1 month after ovarian ponction (end of MAP)
|
Rosenberg self-esteem scale: The score is between 10 and 40. A score below 25 indicates very low self-esteem. A score between 25 and 31 indicates low self-esteem. A score between 31 and 34 indicates average self-esteem. A score between 34 and 39 indicates strong self-esteem. A score above 39 indicates very high self-esteem. |
1 month after ovarian ponction (end of MAP)
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Stéphanie Huberlant, CHU Nimes
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- NIMAO/2019-2/SH-01
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .